Ocugen Inc (OCGN)
0.9509
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
0.96
+0.01
(+0.96%)
After-Hours: 20:00
Ocugen Revenue (Quarterly): 1.141M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.141M |
| March 31, 2024 | 1.014M |
| December 31, 2023 | 6.036M |
| September 30, 2023 | |
| June 30, 2023 | 0.485M |
| March 31, 2023 | 0.443M |
| December 31, 2022 | 2.488M |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 0.043M |
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 |
| Date | Value |
|---|---|
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | 0.003M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.043M
Minimum
Jun 2020
6.036M
Maximum
Dec 2023
1.664M
Average
1.014M
Median
Mar 2024
Revenue (Quarterly) Benchmarks
| Cytokinetics Inc | 0.249M |
| Scholar Rock Holding Corp | -- |
| Mirum Pharmaceuticals Inc | 77.88M |
| SpringWorks Therapeutics Inc | 59.73M |
| NeuroBo Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -15.28M |
| Total Expenses (Quarterly) | 16.59M |
| EPS Diluted (Quarterly) | -0.04 |
| Enterprise Value | 260.88M |
| Profit Margin (Quarterly) | -1.34K% |
| Earnings Yield | -19.98% |
| Normalized Earnings Yield | -19.98 |